The US is communicating regularly with India in bilateral and multilateral channels to discuss the supply of Covid-19 vaccines and inquire about its timeline for restarting vaccine exports. “Vaccinating as much of the developing world, as quickly as possible, is in America’s vital interest, because the uncontrolled spread of the virus inevitably produces more dangerous variants,” an Axios report said.

The United States has been pushing India to restart vaccine exports as it looks to stem the global spread of the Covid pandemic.

The US is communicating regularly with India in bilateral and multilateral channels to discuss the supply of Covid-19 vaccines and inquire about its timeline for restarting vaccine exports, a senior Biden administration official told Reuters.

The supply of Covid vaccines will also be one of the key topics of discussion during the first in-person Quad leadership meeting in US on September 24. Quad is a multilateral alliance of US, India, Australia and Japan.

During their virtual meeting in March this year, the Quad leaders had agreed to work closely on boosting Covid-19 vaccine supply.

However, the initiative was stalled after India was struck by the deadly second wave of the virus.

Since then, India’s vaccine exports took a major hit as the country sought to prioritise immunisation of its population of over 1.3 billion people.

According to Axios, the Biden administration is now looking to push Modi to renew vaccine supply to the world through the global Covax initiative since it wants to mitigate the international spread of the virus.

“Vaccinating as much of the developing world, as quickly as possible, is in America’s vital interest, because the uncontrolled spread of the virus inevitably produces more dangerous variants,” the Axios report said.

“Washington was staying in close touch with India and other Quad partners about the vaccine partnership, and any factors that may affect this project or global vaccine supply, but those discussions were not tied to a specific summit or engagement,” the US official said.

The official noted that Washington had diverted its own supply of raw materials for vaccine production to India in April, given its urgent needs, and global vaccine supply remained a key bottleneck to ending the pandemic.

“We commend India for being one of the largest manufacturers for safe and effective COVID-19 vaccines globally, and we note that COVAX and the world rely heavily on India’s contributions,” the official said. “It’s important for the United States to engage all our allies and partners on these matters so we can take the necessary actions to end this pandemic together.“

However, while US is pushing India to kickstart its vaccine exports, it had stalled its own vaccine exports for months to prioritise shots for its population under the “America First” policy.

Reference: https://health.economictimes.indiatimes.com/news/pharma/why-us-is-pushing-india-to-restart-covid-vaccine-exports/86194407

More News
Global Freight Costs Surge 130%
News · 03/11/2026

Global shipping costs have climbed to $4,000–$4,500 in October from $2,000–$2,500 in February 2026. Freight rates, which had eased through much of 2025 and early 2026 as the demand-supply balance improved, have rebounded sharply in recent months. The increase has brought shipping costs back into focus for businesses dependent on international cargo movement.

READ MORE
FDA Issues Final Guidance on Manufacturing Changes for Biosimilars
News · 03/11/2026

The U.S. Food and Drug Administration (FDA) has finalized guidance outlining how manufacturers should report post-approval manufacturing changes for biosimilar and interchangeable biosimilar products. The guidance provides greater regulatory clarity on changes involving production processes, manufacturing sites, analytical methods, raw materials, and process controls. It aims to ensure product quality while reducing unnecessary regulatory burden.

READ MORE
Biosimilars |  Regulatory Reforms & a Maturing Patent Framework
News · 01/10/2026

A significant uptick in M&A activity in the biosimilars sector is being driven by FDA regulatory reforms, a maturing patent litigation framework and a looming patent cliff — $200 billion of branded products are facing patent expiration by 2030.

READ MORE
Container Rates Edge Lower Ahead of Golden Week as Suez Traffic Returns
News · 01/10/2026

The Drewry World Container Index edged lower this week as falling Asia-Europe rates outweighed firmer pricing on the Transpacific, with carriers preparing another round of blank sailings ahead of China’s Golden Week holiday.

READ MORE
EU: “Forever Chemicals” in a Conflict of Interests
News · 01/09/2026

On 14 July 2026, the European Parliamentary Research Service (EPRS) published a comprehensive briefing on PFAS (per- and polyfluoroalkyl substances), also known as ‘forever chemicals’. The document is intended to serve as a technical basis for MEPs in their upcoming political decisions on PFAS regulation and summarises the current state of scientific knowledge, regulation and procedures.

READ MORE
China Port Congestion
News · 01/09/2026

Following a series of typhoon disruptions in East China during the month of August, major ports including Shanghai and Ningbo continue to experience congestion and operational recovery challenges. Industry reports indicate that vessel schedules, yard operations, and equipment circulation remain affected as terminals work through accumulated backlogs from successive storm events.

READ MORE
EU Microplastics Restriction
News · 03/08/2026

Under REACH Annex XVII Entry 78, the EU has banned the placing on the market of synthetic polymer microparticles (SPMs) unless a specific derogation applies. Derogations exist for essential uses such as:

READ MORE
CLP 2026: New Hazard Classes For Mixtures
News · 02/07/2026

As a result of the amendment of the CLP Regulation (Regulation (EC) No 1272/2008 on the classification, labelling and packaging of substances and mixtures), new hazard classes have entered into force.

READ MORE
EU & US Move to Phase Out Animal Testing
News · 05/06/2026

In a converging policy shift on both sides of the Atlantic, European regulators this week published a roadmap toward fully replacing animal testing for chemical safety assessments, while the US Environmental Protection Agency issued a rare update to its list of alternative test methods.

READ MORE